contraindications: Contraindicated in individuals with prostate or breast carcinoma, polycythaemia, or severe hepatic impairment.
Not indicated for use in women due to virilisation risk.
Hypersensitivity to testosterone enanthate or any excipient in the Rossiaz Lab formulation is an absolute contraindication.
side_effects: Suppression of endogenous testosterone and gonadotropin secretion occurs in all users — this is the primary driver of PCT necessity.
Erythrocytosis: haematocrit elevation above 52% requires dose review and possible therapeutic phlebotomy.
Oestrogen-mediated effects (gynaecomastia, fluid retention) arise from peripheral aromatisation; aromatase inhibitor use should be guided by measured oestradiol levels.
Acne, increased sebum production, and androgenic alopecia in genetically predisposed individuals.
Injection-site reactions including localised pain, swelling, or induration.
monitoring: Serum total testosterone, LH, FSH, oestradiol, haematocrit, and lipid panel at cycle weeks 4 and 8.
Full blood count at cycle end and at PCT weeks 4 and 8 to track haematological and hormonal recovery.
Blood pressure monitoring throughout the cycle; androgenic compounds can contribute to hypertension in susceptible individuals.
pct: Initiate SERM-based PCT 14–16 days after the final Rossiaz Lab Test E 250mg/ml injection.
Standard PCT duration: 4–6 weeks using tamoxifen (20–40mg/day) or clomiphene citrate (25–50mg/day).
Do not begin PCT until serum testosterone has declined sufficiently; premature SERM initiation with elevated circulating androgen produces no meaningful HPTA stimulus.
Confirm recovery via immunoassay before resuming any further anabolic cycle.